162 related articles for article (PubMed ID: 29921237)
1. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model.
Li Y; Du Y; Sun T; Xue H; Jin Z; Tian J
BMC Cancer; 2018 Jun; 18(1):669. PubMed ID: 29921237
[TBL] [Abstract][Full Text] [Related]
2. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
3. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
4. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
5. Enhanced antitumor efficacy through microwave ablation in combination with immune checkpoints blockade in breast cancer: A pre-clinical study in a murine model.
Zhu J; Yu M; Chen L; Kong P; Li L; Ma G; Ge H; Cui Y; Li Z; Pan H; Xie H; Zhou W; Wang S
Diagn Interv Imaging; 2018 Mar; 99(3):135-142. PubMed ID: 29398572
[TBL] [Abstract][Full Text] [Related]
6. Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human
Burova E; Hermann A; Dai J; Ullman E; Halasz G; Potocky T; Hong S; Liu M; Allbritton O; Woodruff A; Pei J; Rafique A; Poueymirou W; Martin J; MacDonald D; Olson WC; Murphy A; Ioffe E; Thurston G; Mohrs M
Mol Cancer Ther; 2019 Nov; 18(11):2051-2062. PubMed ID: 31395688
[TBL] [Abstract][Full Text] [Related]
7. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor.
Shindo Y; Yoshimura K; Kuramasu A; Watanabe Y; Ito H; Kondo T; Oga A; Ito H; Yoshino S; Hazama S; Tamada K; Yagita H; Oka M
Anticancer Res; 2015 Jan; 35(1):129-36. PubMed ID: 25550543
[TBL] [Abstract][Full Text] [Related]
9. Identification and Characterization of MEDI4736, an Antagonistic Anti-PD-L1 Monoclonal Antibody.
Stewart R; Morrow M; Hammond SA; Mulgrew K; Marcus D; Poon E; Watkins A; Mullins S; Chodorge M; Andrews J; Bannister D; Dick E; Crawford N; Parmentier J; Alimzhanov M; Babcook JS; Foltz IN; Buchanan A; Bedian V; Wilkinson RW; McCourt M
Cancer Immunol Res; 2015 Sep; 3(9):1052-62. PubMed ID: 25943534
[TBL] [Abstract][Full Text] [Related]
10. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
11. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
12. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
13. Combination Therapy with NHS-muIL12 and Avelumab (anti-PD-L1) Enhances Antitumor Efficacy in Preclinical Cancer Models.
Xu C; Zhang Y; Rolfe PA; Hernández VM; Guzman W; Kradjian G; Marelli B; Qin G; Qi J; Wang H; Yu H; Tighe R; Lo KM; English JM; Radvanyi L; Lan Y
Clin Cancer Res; 2017 Oct; 23(19):5869-5880. PubMed ID: 28679778
[No Abstract] [Full Text] [Related]
14. Antitumor Effect of Programmed Death-1 (PD-1) Blockade in Humanized the NOG-MHC Double Knockout Mouse.
Ashizawa T; Iizuka A; Nonomura C; Kondou R; Maeda C; Miyata H; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Katano I; Ito M; Akiyama Y
Clin Cancer Res; 2017 Jan; 23(1):149-158. PubMed ID: 27458246
[TBL] [Abstract][Full Text] [Related]
15. Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.
Esser AK; Schmieder AH; Ross MH; Xiang J; Su X; Cui G; Zhang H; Yang X; Allen JS; Williams T; Wickline SA; Pan D; Lanza GM; Weilbaecher KN
Nanomedicine; 2016 Jan; 12(1):201-11. PubMed ID: 26515754
[TBL] [Abstract][Full Text] [Related]
16. Mechanism exploration of Zoledronic acid combined with PD-1 in the treatment of hepatocellular carcinoma.
Fan X; Yan Z; Lin Y; Wang Q; Jiang L; Yao X; Dong L; Chen L; Zhao T; Zhao J; Hu H; Wang H
Cancer Immunol Immunother; 2024 Mar; 73(4):62. PubMed ID: 38430249
[TBL] [Abstract][Full Text] [Related]
17. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer.
Xu X; Huang Z; Zheng L; Fan Y
Int J Cancer; 2018 Jun; 142(11):2344-2354. PubMed ID: 29318609
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic acid prevents the tumor-promoting effects of mesenchymal stem cells via MCP-1 dependent recruitment of macrophages.
Jia XH; Du Y; Mao D; Wang ZL; He ZQ; Qiu JD; Ma XB; Shang WT; Ding D; Tian J
Oncotarget; 2015 Sep; 6(28):26018-28. PubMed ID: 26305552
[TBL] [Abstract][Full Text] [Related]
20. Concomitant targeting of programmed death-1 (PD-1) and CD137 improves the efficacy of radiotherapy in a mouse model of human BRAFV600-mutant melanoma.
Kroon P; Gadiot J; Peeters M; Gasparini A; Deken MA; Yagita H; Verheij M; Borst J; Blank CU; Verbrugge I
Cancer Immunol Immunother; 2016 Jun; 65(6):753-63. PubMed ID: 27160390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]